Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men
- PMID: 18005202
- PMCID: PMC2647139
- DOI: 10.1111/j.1464-410X.2007.07332.x
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men
Abstract
Objective: To examine the associations of serum lipids and lipoproteins with benign prostatic hyperplasia (BPH) in community-dwelling men.
Subjects and methods: This analysis was conducted within the Rancho Bernardo Study, a prospective, community-based cohort study. BPH was defined as a history of prostate surgery for other than cancer, or a medical diagnosis of BPH. Logistic regression modelling, with adjustments for age and stratification by diabetes diagnosis, was used to estimate the odds ratio (OR) of BPH associated with fasting serum concentrations of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and the triglyceride to HDL ratio.
Results: Among 531 eligible participants, 259 (48%) reported BPH and 272 (52%) reported no BPH. Men with BPH, with a mean (range) age of 75.8 (76.1-80.1) years, were older than men without BPH , at 72.7 (72.4-74.0) years. There were no significant associations of total cholesterol (P trend, 0.52), HDL cholesterol (0.56), triglycerides (0.30), or triglyceride to HDL ratio (0.13) with the risk of BPH. In a subset analysis in men with diabetes, those in the highest tertile (>133 mg/dL) of LDL cholesterol, compared with those in the lowest tertile (<110 mg/dL), were four times more likely to have BPH (odds ratio 4.00, 95% confidence interval 1.27-12.63, P trend 0.02). These results were not explained by the use of statins.
Conclusions: In these community-dwelling men, higher serum LDL was associated with a greater risk of BPH among diabetics. These data suggest that diabetic men with increased LDL cholesterol are at greater risk of BPH. This observation is consistent with the concept that cardiac risk factors are involved with the pathogenesis of BPH.
Similar articles
-
Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects.Front Nutr. 2022 Oct 3;9:999995. doi: 10.3389/fnut.2022.999995. eCollection 2022. Front Nutr. 2022. PMID: 36263299 Free PMC article.
-
Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.Blood Press. 1999;8(1):29-36. doi: 10.1080/080370599438365. Blood Press. 1999. PMID: 10412880
-
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease.Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1229-1238. doi: 10.1161/ATVBAHA.120.315828. Epub 2021 Jan 28. Arterioscler Thromb Vasc Biol. 2021. PMID: 33504178 Free PMC article.
-
[Diabetic dyslipidaemia and the atherosclerosis].Orv Hetil. 2016 May 8;157(19):746-52. doi: 10.1556/650.2016.30441. Orv Hetil. 2016. PMID: 27133274 Review. Hungarian.
-
Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease.Anadolu Kardiyol Derg. 2004 Sep;4(3):236-45. Anadolu Kardiyol Derg. 2004. PMID: 15355827 Review.
Cited by
-
Associated Factors for Prostate Enlargement in Chinese Adult Men Aged <40 Receiving Checkups.Int J Clin Pract. 2022 Aug 11;2022:4792451. doi: 10.1155/2022/4792451. eCollection 2022. Int J Clin Pract. 2022. PMID: 36016826 Free PMC article.
-
Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.Ther Adv Urol. 2017 Dec 7;10(2):79-92. doi: 10.1177/1756287217742837. eCollection 2018 Feb. Ther Adv Urol. 2017. PMID: 29434675 Free PMC article. Review.
-
The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.Cancer Causes Control. 2011 Mar;22(3):417-26. doi: 10.1007/s10552-010-9713-4. Epub 2010 Dec 19. Cancer Causes Control. 2011. PMID: 21170754 Free PMC article.
-
Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.BJU Int. 2020 Feb;125(2):226-233. doi: 10.1111/bju.14905. Epub 2019 Sep 27. BJU Int. 2020. PMID: 31479563 Free PMC article. Clinical Trial.
-
Metabolic syndrome is predictive of lower urinary tract symptom improvement after holmium laser enucleation of the prostate for benign prostatic obstruction.Int Urol Nephrol. 2017 Jul;49(7):1105-1110. doi: 10.1007/s11255-017-1580-4. Epub 2017 Mar 30. Int Urol Nephrol. 2017. PMID: 28361474
References
-
- Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005 Apr;173(4):1256–61. - PubMed
-
- Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994 Dec 1;140(11):989–1002. - PubMed
-
- Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004 Feb 15;159(4):390–7. - PubMed
-
- Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005 Jul;96(1):88–92. - PubMed